Ivo Francischetti and Colleagues on Glycoprotein VI Contributing to Platelet Activation in HIT
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn:
”Glycoprotein VI is a receptor for the PF4/anti-PF4 IgG complex and contributes to platelet activation in heparin-induced thrombocytopenia (HIT)
By Ivo Francischetti, Kathryn Dane, Ed Galgo, Michael B. Streiff, and John F. Andersen
Heparin-induced thrombocytopenia (HIT) involves platelet activation by PF4/anti-PF4 complexes.
This study identifies glycoprotein VI (GPVI) as a receptor for these complexes, enhancing PF4 binding (Kd ≈ 30–100 nM) and platelet aggregation via FcγRIIA.
GPVI blockade (anti-GPVI antibodies, ACT017) suppressed activation, while AlphaFold modeling revealed electrostatic interactions between GPVI and PF4/IgG.
These findings position GPVI as a potential therapeutic target in HIT.”
Read the full article in JTH.
Article: Glycoprotein VI is a receptor for the PF4/anti-PF4 IgG complex and contributes to platelet activation in heparin-induced thrombocytopenia (HIT)
Authors: Ivo Francischetti, Kathryn Dane, Ed Galgo, Michael Streiff, John Andersen

Stay updated on all scientific advances with Hemostasis Today.
-
Oct 11, 2026, 14:29Mohamed Magdy: Essential Thrombocythemia Summary
-
Oct 11, 2026, 14:28Mavis Agnes Kisakye: Expanding Access to Life-Saving Treatment for Bleeding Disorders
-
Oct 11, 2026, 14:18Amber Paratore Sanchez: A Novel Double-Draw Approach to Apheresis Access
-
Oct 11, 2026, 14:09Joseph Sci Borg: The Haemoglobin Switch as a Programmable Biological Transition
-
Oct 11, 2026, 14:07Robert Sidonio։ Bleeding Care for Women and Girls With Hemophilia
-
Oct 11, 2026, 13:58Jose M. Adrover: Postdoctoral Fellowship on Neutrophils and Cancer-Associated Thrombosis
-
Oct 11, 2026, 13:42Natalie Arnold։ Uncovering Hidden Cardiovascular Risk in Apparently Low-Risk Individuals
-
Oct 11, 2026, 12:11Carmine Siniscalchi: Could LDL Cholesterol Help Us Better Predict Bleeding Risk in Patients with VTE?
-
Oct 11, 2026, 12:03What is ITP? Raising Awareness for Immune Thrombocytopenia – ITP Australia and New Zealand